期刊
JOURNAL OF CONTROLLED RELEASE
卷 316, 期 -, 页码 22-33出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2019.10.037
关键词
LAT1; ATB(0,+); CPT-11; Amino acid transporter; Dual-targeted liposomes; Active drug loading
资金
- National Nature Science Foundation of China [U1608283]
- Career Development Program for Young and Middle-aged Teachers in Shenyang Pharmaceutical University
As the demand for nutrients in malignant proliferation of tumors increases, the L-type amino acid transporter 1(LAT1) and amino acid transporter B-0,B-+ (ATB(0,+)) of tumor cells are more highly expressed than normal cells which can be used as new targets for active targeting of cancer. However, drug delivery systems often require multi-target design to achieve simultaneous targeting of different receptors or transporters due to the heterogeneity of the tumor. Here we utilized triethylamine-sucrose octasulfate gradient to actively encapsulate irinotecan into the introliposomal aqueous phase. Targeted ability was achieved through inserting different amino acids modified polyethylene glycol monostearate into the liposomes, and found that glutamate-liposomes can be targeted to LAT1, lysine-liposomes can be targeted to ATB(0,+), and inspiringly, tyrosine-liposomes can be simultaneously targeted to LAT1 and ATB(0,+). The tyrosine-modified liposomes showed the highest cellular uptake in BxPC-3 and MCF-7 cells which were highly expressed both LAT1 and ATB(0,+). Moreover, we validated their targeting capabilities and elucidated the transport mechanism of LAT1 and ATB(0,+)-mediated endocytosis. The tumor inhibition rate of tyrosine-modified liposomes greatly increased from 39% to 87% compared with commercially available liposomes loaded CPT-11(Onivyde (R)). Overall, it showed a good application prospect for efficient tumor therapy and industrial production.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据